Fulvestrant in Treating Patients With Recurrent Prostate Cancer

Stopped early · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Estrogen may cause the growth of prostate cancer cells. Hormone therapy using fulvestrant may fight prostate cancer by blocking the use of estrogen by the tumor cells. PURPOSE: This phase II trial is studying how well fulvestrant works in treating patients with recurrent prostate cancer.

Key facts

Study ID

NCT00217464

Run by

Roswell Park Cancer Institute

People needed

17

Starts

2004-06-01

Expected to finish

2010-03-01

Last updated by the study team

2015-04-16

Who can join

Age: any. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Roswell Park Cancer Institute — Buffalo, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.